Effectiveness – Page 2

Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment

4 months ago talkbio0Tagged Ability to perform cognitive activity, Antipsychotic Agents, Brilaroxazine, Effectiveness, Long-term, Negative, Safety, Schizophrenia, Symptoms aspect

Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning

SIGA’s TPOXX Fails to Demonstrate Efficacy in Treating Mild to Moderate Mpox Cases: STOMP Study Results

4 months ago talkbio0Tagged 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one, antiviral treatment, Clinical Research, Effectiveness, Safety, Secretory Immunoglobulin A, STOMP, Technology, tecovirimat, Tpoxx

SIGA Technologies, TPOXX, Tecovirimat, Mpox, STOMP Study, Antiviral Treatment, Efficacy, Safety Profile

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

4 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

Novartis Reveals Sustained Efficacy and Safety of Fabhalta in Patients Switching from Anti-C5 Therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH)

5 months ago talkbio0Tagged anti-C5, Avoidance, Blood Transfusion, Effectiveness, Fabhalta, Hemoglobin improvement, Iptacopan, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Safety, Switching therapies

Fabhalta (iptacopan), Paroxysmal Nocturnal Hemoglobinuria (PNH), Anti-C5 therapies, Efficacy and safety, Switching therapies, Hemoglobin improvement, Transfusion avoidance